Documents

Disciplined execution and innovation drive margin recovery, growth, and capital strength.

Q2 2026 delivered strong revenue and EPS growth, prompting raised full-year guidance.

All management proposals passed; shareholder proposal on written consent threshold failed.

Q1 2026 delivered strong growth, raised guidance, and advanced tech-driven, value-based care initiatives.

Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare.

2025 results exceeded expectations with strong growth, margin progress, and positive 2026 outlook.

Targeting mid-teens EPS CAGR through 2028, driven by tech-enabled growth and new platform launch.

Record Q3 results and raised 2025 outlook, despite a $5.7B impairment in healthcare delivery.

Raised full-year EPS guidance after strong Q2, with robust pharmacy and Aetna results offsetting Oak Street pressures.

Raised 2025 EPS guidance after strong Q1, exiting ACA exchanges, and expanding Wegovy access.

2025 guidance targets adjusted EPS of $5.75–$6 amid Aetna recovery and ongoing cost pressures.